However, in light of the good discrimination between controls and AD patients using [18F]THK5317 retention in the putamen, and despite the moderate non-specific retention in this region in the yHC group, it could conceivably be hypothesised that [18F]THK5317 is able to successfully detect underlying tau pathology in this region [31]. The gene discussed is MAPT; the disease is Alzheimer disease.